Camlin Fine Sciences Limited has successfully completed its postal ballot process, with shareholders approving the resolution for increase in Authorized Share Capital and consequent amendment to Clause V of the Memorandum of Association of the Company. The resolution was passed with requisite majority on May 7, 2026, being the last date of voting. The outcome was disclosed to the stock exchanges on May 8, 2026, in compliance with Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Postal Ballot Process Overview

The postal ballot process was initiated pursuant to a letter dated April 7, 2026, seeking consent of the members of the Company through remote e-voting. The cut-off date for determining eligible equity shareholders was Friday, April 3, 2026. The voting period commenced on Wednesday, April 8, 2026, at 9:00 a.m. (IST) and concluded on Thursday, May 7, 2026, at 5:00 p.m. (IST). Voting was conducted in electronic mode only, facilitated through the portal of National Securities Depository Limited (NSDL). The total number of shareholders on the cut-off date stood at 53,231.

Voting Results Summary

The following table presents the consolidated voting results across all shareholder categories for the resolution on increase in Authorized Share Capital:

Category-Wise Voting Breakdown

The voting participation and results varied across shareholder categories. The Promoter and Promoter Group cast all their votes in favour, while Public Institutions also voted unanimously in favour. A marginal dissent was recorded from the Public Non-Institutions category. The detailed category-wise results are as follows:

Scrutinizer's Report

The Scrutinizer's Report dated May 8, 2026, was submitted by J. H. Ranade, Partner of JHR & Associates, Practicing Company Secretaries, Thane (FCS: 4317, CP: 2520), who was appointed by the Board of Directors to oversee the postal ballot voting process. The report was prepared pursuant to Section 108 and Section 110 of the Companies Act, 2013, read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014. After the close of the remote e-voting period, votes were unblocked and a detailed voting summary report was downloaded from the NSDL portal in the presence of two independent witnesses.

The ballot-wise summary of votes cast for the special resolution is presented below:

Voted in Favour:

Voted Against:

No invalid, less-voted, or abstained ballots were recorded. The promoter and promoter group were not identified as interested parties in the resolution. The voting results along with the Scrutinizer's Report are available on the Company's website at www.camlinfs.com . The disclosure was signed by Rahul Sawale, Company Secretary & VP Legal, on behalf of Camlin Fine Sciences Limited.

Camlin Fine Sciences Limited has filed a draft tender offer with the French Stock Markets Authority (AMF) for a simplified cash tender offer (offre publique d'achat simplifiée, or OPAS) targeting the remaining shares of Vinpai's share capital not held by the company. The offer is priced at EUR 3.60 per Vinpai share, consistent with the price paid during the earlier Block Acquisition. This disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Background: Acquisition of Majority Stake in Vinpai

Camlin Fine Sciences, described as a leading Indian group in shelf life solutions for flavour and health & wellness ingredients, completed the acquisition of a majority stake in Vinpai (ISIN: FR001400AXT1; mnémonique: ALVIN), listed on Euronext Growth Paris, on November 27, 2025. The acquisition was executed by way of contribution in kind. Additionally, the company proceeded with the conversion of convertible bonds, allowing it to subscribe to 1,100,000 new ordinary shares of Vinpai that were issued to it.

The key details of the company's current holding in Vinpai are summarised below:

Draft Offer Filed with the AMF

On May 4, 2026, Camlin Fine Sciences filed its draft tender offer with the AMF pursuant to Articles 234-2 and 235-2 of the General Regulation of the AMF. The OPAS targets the remaining shares of Vinpai's share capital that are not held by the company. The timetable and terms and conditions of the OPAS are detailed in the Draft Offer Document, which remains subject to review by the AMF.

The Draft Offer Document is available on the websites of the AMF ( www.amf-france.org ), of Camlin Fine Sciences ( www.camlinfns.com ), and of Vinpai ( https://vinpai-finance.com/fr/ ).

Independent Expert Opinion and Board Approval

Crowe HAF was appointed as an independent expert on March 14, 2025 by the Board of Directors of Vinpai, upon the recommendation of its ad hoc committee, to review the fairness of the financial terms of the OPAS. On April 27, 2026, Crowe HAF issued its report, concluding as follows:

"In summary, the Offer provides the opportunity to the Company's shareholders to obtain immediate liquidity of its participation at a price equal to price paid in the Block Acquisition, and which includes premiums over the evaluation methods implemented by us. On the basis of all these factors, it is our opinion that the terms of the Simplified Tender Offer, optional offer for minority shareholders and proposing a price of EUR 3.60 per Vinpai share, are fair from a financial standpoint for the minority shareholders of Vinpai."

Based on the conclusions of the fairness opinion issued by Crowe HAF and the recommendation of the ad hoc committee, Vinpai's Board of Directors unanimously issued a reasoned favorable opinion on the OPAS. The independent expert's report is reproduced in full in the appendix to the company's response document.

Squeeze-Out Procedure: No Longer Intended

Camlin Fine Sciences has also clarified that it no longer intends to ask the AMF to implement a squeeze-out procedure for Vinpai shares from the Euronext Growth Paris market. The advisors to Camlin Fine Sciences for this transaction include Allinvest Securities as the presenting institution and Fontaine Avocats as legal advisor.

This disclosure was made by Rahul Sawale, Company Secretary & VP Legal of Camlin Fine Sciences Limited, on May 4, 2026.